Mark T. Fleming
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Papers in
-
- Prostate Cancer Treatment and Research 28
- Prostate Cancer Diagnosis and Treatment 7
- Renal cell carcinoma treatment 3
- Surgery 19
- Bladder and Urothelial Cancer Treatments 19
- Co-authors
- Howard I. Scher (5 shared papers)Johann Sebastian De Bono (6 shared papers)Fred Saad (2 shared papers)Karim S. Fizazi (4 shared papers)Neal D. Shore (6 shared papers)Andrew J. Armstrong (2 shared papers)Cora Nanette Sternberg (2 shared papers)John Daniel Hainsworth (1 shared paper)
- Journals
- Annals of Oncology (10 papers)The Lancet Oncology (5 papers)The Journal of Urology (5 papers)Clinical Cancer Research (4 papers)Clinical Genitourinary Cancer (3 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Mark T. Fleming
61 papers receiving 10.4k citations
Mark T. Fleming's Hit Papers
Peers
Comparison fields: 5 of 94
- Pulmonary and Respiratory Medicine 4.4k
- Oncology 2.7k
- Surgery 2.6k
- Cancer Research 475
- Radiology, Nuclear Medicine and Imaging 489
Countries citing papers authored by Mark T. Fleming
This map shows the geographic impact of Mark T. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Fleming more than expected).
Fields of papers citing papers by Mark T. Fleming
This network shows the impact of papers produced by Mark T. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Fleming. The network helps show where Mark T. Fleming may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark T. Fleming, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3736 |
| 2 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 3053 |
| 3 | Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2019 | 1066 |
| 4 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 490 |
| 5 | 2021 | 229 | |
| 6 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 212 |
| 7 | Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Hit paper breakdown → | 2022 | 138 |
| 8 | 2011 | 127 | |
| 9 | 2009 | 118 | |
| 10 | 2020 | 108 | |
| 11 | 2017 | 95 | |
| 12 | 2020 | 91 | |
| 13 | 2019 | 79 | |
| 14 | 2022 | 75 | |
| 15 | 2019 | 70 | |
| 16 | 2023 | 69 | |
| 17 | 2006 | 62 | |
| 18 | 2010 | 57 | |
| 19 | 2013 | 57 | |
| 20 | 2023 | 56 |
About Mark T. Fleming
Mark T. Fleming is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Radiology, Nuclear Medicine and Imaging and Geriatrics and Gerontology, having authored 61 papers that have together received 10.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (28 papers), Bladder and Urothelial Cancer Treatments (19 papers), Prostate Cancer Diagnosis and Treatment (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Medical Imaging Techniques and Applications (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Renal cell carcinoma treatment (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.4k citations), Oncology (2.7k citations), Surgery (2.6k citations), Cancer Research (475 citations) and Radiology, Nuclear Medicine and Imaging (489 citations). Mark T. Fleming has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Howard I. Scher, Johann Sebastian De Bono, Fred Saad, Karim S. Fizazi, Neal D. Shore, Andrew J. Armstrong, Cora Nanette Sternberg, John Daniel Hainsworth, Kim N. Chi and Ronald de Wit. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, The Journal of Urology, Clinical Cancer Research and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.